Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
All VideosCURE ConnectionsCURE Expert Connections®CURE Speaking OutCURE TVEducated Patient Sound BitesOn Demand: Webinars
Conference Coverage Conference Listing
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story
Subscribe
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
LeukemiaLeukemiaLeukemia
Lung Cancer
LymphomaLymphomaLymphomaLymphoma
Rare CancersRare Cancers
Sarcoma
Skin Cancer/Melanoma
Thyroid Cancer
Spotlight -
  • Blogs
  • Breast Cancer Webinar Series
  • Cancer Horizons
  • Clinical Trial Corner
  • Heal®
  • Publications
  • Videos
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
LeukemiaLeukemiaLeukemia
Lung Cancer
LymphomaLymphomaLymphomaLymphoma
Rare CancersRare Cancers
Sarcoma
Skin Cancer/Melanoma
Thyroid Cancer
    • Subscribe
Advertisement

News

Article

March 8, 2025

FDA Approves Biosimilars for Cancer-Related Skeletal Events

Author(s):

Alex Biese

Fact checked by:

Darlene Dobkowski, MA

Key Takeaways

  • Stoboclo and Osenvelt, biosimilars of Prolia and Xgeva, are FDA-approved for bone health in cancer patients, available in the U.S. by June 2025.
  • Xgeva treats bone issues in cancer patients, while Prolia increases bone mass in high-risk adults, including those undergoing cancer therapies.
  • Phase 3 trials demonstrated Stoboclo and Osenvelt's equivalent effectiveness, safety, and pharmacodynamics compared to their reference drugs.
  • Biosimilars expand therapeutic options, offering cost savings and increased access in oncology, immunology, and ophthalmology.
SHOW MORE

The FDA has approved Stoboclo and Osenvelt to address skeletal issues faced by patients with cancer.

green background with white text indicating FDA Approval, What You Need to Know

FDA approves Stoboclo and Osenvelt biosimilars for bone health during cancer treatment.

The Food and Drug Administration (FDA) has approved Stoboclo (CT-P41, denosumab-bmwo) and Osenvelt (CT-P41, denosumab-bmwo), biosimilars referencing Prolia (denosumab) and Xgeva (denosumab), to protect bone health in patients undergoing cancer treatment.

The approval was announced in a news release from biopharmaceutical company Celltrion. According to the news release, Stoboclo and Osenvelt are expected to be available in the United States in June 2025.

Biosimilar drugs, according to the National Cancer Institute, are very much like another biological drug, referred to as the reference drug, that has already been approved by the FDA. Additionally, these drugs must be shown to be as safe as, work as well as and work in a similar way as the reference drug.

Among patients with cancer, Xgeva is approved to treat giant cell tumors of the bone that cannot be removed by surgery and hypercalcemia of malignancy that got worse after treatment with bisphosphonates, according to the National Cancer Institute. It is also approved to prevent broken bones or other bone problems caused by multiple myeloma, or by solid tumors that have spread to the bone, according to the National Cancer Institute.

Prolia is approved to increase bone mass among adults with a high risk of breaking bones and is used among patients with breast cancer receiving aromatase inhibitor therapy and patients with prostate cancer receiving androgen deprivation therapy, the National Cancer Institute noted.

The drug is also being studied in the treatment of other conditions and types of cancer, according to the National Cancer Institute.

Glossary:

Hypercalcemia: High levels of calcium in the blood.

Bisphosphonates: Medications used to treat bone conditions.

Aromatase inhibitor therapy: Treatments that lower estrogen levels in the body.

Androgen deprivation therapy: Treatment to lower the level of androgens in the body.

Pharmacodynamics: The study of the biochemical and physiological effects of drugs and the mechanisms of their actions.

Pharmacokinetics: The activity of drugs in the body over a period of time.

Immunogenicity: The ability of a substance that contains antigens to cause the body to make an immune response against that substance.

“[Prolia and Xgeva are] used to improve or protect bone health in patients with osteoporosis or those undergoing various cancer treatments and as a therapy for a lifetime for postmenopausal [patients with osteoporosis],” said Jean-Yves Reginster, Professor of Medicine, Protein Research Chair, Biochemistry Department, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia and Director WHO Collaborating Centre for Epidemiology of Musculoskeletal Health and Aging, Liège, Belgium. "Biosimilars have expanded into new therapeutic areas such as immunology, oncology and ophthalmology, as they continue to offer significant cost-saving potential while expanding patient access. Having a [Prolia and Xgeva] product with a clinically proven track record in quality and safety is a valuable addition for my patients."

The approval, according to the news release, is based on data including results of phase 3 clinical trials among postmenopausal women with osteoporosis intended to evaluate the effectiveness, pharmacodynamics, pharmacokinetics, safety and immunogenicity of Stoboclo and Osenvelt in reference to Prolia and Xgeva, with study results demonstrating that the former had equivalent effectiveness and pharmacodynamics to the latter, with similar pharmacokinetics and comparable safety and immunogenicity.

"The approval of Stoboclo and Osenvelt is another step forward in our efforts to deliver cost-effective and high-quality treatments that address critical unmet needs in osteoporosis-related fracture as well as cancer-related skeletal events," said Thomas Nusbickel, Chief Commercial Officer at Celltrion USA, in the news release. "Patients deserve therapeutic options that have the potential to make real impacts on their care and their lives."

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Dr. Masey Ross explains how biomarker testing, patient history, and quality-of-life concerns guide treatment decisions in metastatic breast cancer.
Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy.
Image of women with text.
Image of man with text.
Image of Dr. with text.
Image of two doctors and text.
Image of two doctors with text.
Imiage of two doctors with text.
Image of thumbnail.
Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.
Related Content
Advertisement
Bria-IMT plus a checkpoint inhibitor improved survival versus Trodelvy and chemo in patients with heavily pretreated metastatic breast cancer: © stock.adobe.com.
July 15th 2025

Bria-IMT Improves Survival in Patients With Metastatic Breast Cancer

Spencer Feldman
Bria-IMT plus a checkpoint inhibitor improved survival versus Trodelvy and chemo in patients with heavily pretreated metastatic breast cancer.
cancer horizons podcast logo: a white microphone on a blue background
March 4th 2024

Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

Alex Biese Brielle Benyon
In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.
Image of man with text.
July 12th 2025

Identifying Patients Who Will Benefit From Intensified Prostate Cancer Treatment

Ryan Scott
Dr. Nicholas James shares why it’s important to identify which patients with high-risk, non-metastatic prostate cancer will benefit from intensified treatment.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
February 12th 2024

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
Image of women.
July 10th 2025

Diagnosis Day: What I Felt, What I Learned

Patti McGee
I found a lump and was shocked to learn it was breast cancer, but over 22 years I’ve learned healing takes time, asking for help is strength, and hope grows.
Image of prostate
July 10th 2025

Long-Term Outcomes Support NCCN Guidelines for Prostate Cancer

Ryan Scott
Patients with nonmetastatic prostate cancer treated according to NCCN Guidelines are more likely to die of other natural causes than from their cancer.
Related Content
Advertisement
Bria-IMT plus a checkpoint inhibitor improved survival versus Trodelvy and chemo in patients with heavily pretreated metastatic breast cancer: © stock.adobe.com.
July 15th 2025

Bria-IMT Improves Survival in Patients With Metastatic Breast Cancer

Spencer Feldman
Bria-IMT plus a checkpoint inhibitor improved survival versus Trodelvy and chemo in patients with heavily pretreated metastatic breast cancer.
cancer horizons podcast logo: a white microphone on a blue background
March 4th 2024

Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

Alex Biese Brielle Benyon
In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.
Image of man with text.
July 12th 2025

Identifying Patients Who Will Benefit From Intensified Prostate Cancer Treatment

Ryan Scott
Dr. Nicholas James shares why it’s important to identify which patients with high-risk, non-metastatic prostate cancer will benefit from intensified treatment.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
February 12th 2024

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
Image of women.
July 10th 2025

Diagnosis Day: What I Felt, What I Learned

Patti McGee
I found a lump and was shocked to learn it was breast cancer, but over 22 years I’ve learned healing takes time, asking for help is strength, and hope grows.
Image of prostate
July 10th 2025

Long-Term Outcomes Support NCCN Guidelines for Prostate Cancer

Ryan Scott
Patients with nonmetastatic prostate cancer treated according to NCCN Guidelines are more likely to die of other natural causes than from their cancer.
About Us
Advertise / Support
Editorial Board
Contact Us
CancerNetwork.com
TargetedOnc.com
OncLive.com
OncNursingNews.com
Terms & Conditions
Privacy
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.